
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMND08
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
Details : BMND08 is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : BMND08
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
Details : 5-MeO-DMT is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 06, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease
Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is an oral formulation of a natural psychedelic called 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for the potential treatment of depression and anxiety in Alzheimer’s disease.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (“DMT”) for Treatment-Resistant Depression, possible to scale-up treatments without the need to train a whole new generation of mental health professionals.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triptax could be used as an API to treat depression, specifically Treatment-Resistant Depression, MDD in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat current depressive episodes...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : Triptax
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Universidade Federal do Rio Grande do Norte
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of DMT in Healthy Adults
Details : N,N-Dimethyltryptamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Universidade Federal do Rio Grande do Norte
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trial is designed with fixed ascending two-dose, concentration-response study, allowing BMND01 (N,N-dimethyltryptamine) to be rapidly delivered directly into the systemic circulation in approximately 10 minutes, bypassing first-pass metabolism.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 (5-Methoxy-N,N-dimethyltryptamine) novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
